In cellular models of castration-resistant prostate cancer (CRPC), ARCC-4 was more effective at inducing apoptosis and inhibiting proliferation of AR-amplified prostate cancer cells compared to its parent compound, enzalutamide. Here, AR is linked to prostate cancer.